The MSK JV is a significant strategic validation for SOPHiA's AI platform and could drive long-term revenue growth through expanded diagnostics deployment and biopharma partnerships. However, the MOU is non-binding and specifics are TBD — monitor for definitive agreements and financial terms in coming quarters. The stock may see a positive reaction on the partnership's prestige, but near-term financial impact is uncertain.
Price Chart
Executive Summary
SOPHiA GENETICS announced a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) to form a joint venture aimed at creating a precision medicine hub for next-generation precision oncology. The JV would combine MSK's clinical data and expertise with SOPHiA's AI platform (SOPHiA DDM) to develop and deploy new diagnostic and therapeutic capabilities globally. The specifics of the initiative have yet to be finalized, and no financial terms were disclosed.
Key Facts
- SOPHiA GENETICS signed an MOU with Memorial Sloan Kettering Cancer Center to form a joint venture for a precision medicine hub.
- The hub would combine MSK's clinical data and expertise with SOPHiA's AI platform (SOPHiA DDM) to develop next-generation precision oncology tools.
- SOPHiA DDM has analyzed over 2.5 million cases since 2014; MSK has sequenced over 150,000 tumor samples since 2014.
- Specifics of the initiative have yet to be finalized; no financial terms or timeline were disclosed.
- The MOU builds on prior successful license agreements between the two institutions for MSK-IMPACT and MSK-ACCESS assays.
Financial Impact
No financial terms disclosed; potential long-term revenue opportunity from expanded platform adoption and biopharma partnerships.
Risk Factors
- JV specifics are not finalized; the MOU is non-binding and may not lead to a definitive agreement.
- No financial terms disclosed — potential dilution or capital requirements for the JV are unknown.
- Execution risk in integrating MSK's data and clinical workflows with SOPHiA's platform.
- Regulatory and commercialization risks for new diagnostic products developed through the hub.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-040630 |
| Document: sophiamsk-pressreleasevf.htm | 0001628280-26-040630 |
| Document: 0001628280-26-040630-index-headers.html | 0001628280-26-040630 |
| Document: 0001628280-26-040630-index.html | 0001628280-26-040630 |
| Document: 0001628280-26-040630.txt | 0001628280-26-040630 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | Insider Cluster | $7.29 $7.05 | ▼ −3.29% | ▼ −2.28% | $7.35 (+0.82%) |
Oct 5, 2026 21d ago | 144 | $7.38 $7.09 | ▼ −3.93% | ▼ −3.79% | $7.35 (−0.41%) |
Sep 16, 2026 5w ago | Insider Cluster | $8.53 $8.26 | ▼ −3.17% | ▼ −4.02% | $7.35 (−13.83%) |
Sep 14, 2026 6w ago | Insider Cluster | $7.96 $8.07 | ▲ +1.38% | ▼ −0.73% | $7.35 (−7.66%) |
Aug 31, 2026 8w ago | Insider Cluster | $8.43 $7.68 | ▼ −8.84% | ▼ −8.92% | $7.35 (−12.76%) |
Aug 26, 2026 8w ago | Insider Cluster | $8.92 $8.30 | ▼ −6.95% | ▼ −7.22% | $7.35 (−17.60%) |
Aug 25, 2026 8w ago | 144 | $8.53 $8.28 | ▲ +2.93% | ▲ +2.81% | $7.35 (+13.83%) |
Aug 21, 2026 9w ago | Insider Cluster | $8.45 $8.40 | ▼ −0.59% | ▼ −1.06% | $7.35 (−13.02%) |
Aug 21, 2026 9w ago | Insider Cluster | $8.45 $8.40 | ▼ −0.59% | ▼ −1.06% | $7.35 (−13.02%) |
Aug 14, 2026 10w ago | Insider Cluster | $7.63 $8.45 | ▼ −10.75% | ▼ −11.94% | $7.35 (+3.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers